Fintech▲ 70

Neurolief Secures $6M Post-FDA Approval Funding

Prnewswire·March 30, 2026 at 11:30 AM

Neurolief, a medical technology company focused on mental health, has secured an additional $6 million in investment following the FDA approval of its Proliv™Rx therapy. This funding will be used to expand patient access to its brain neuromodulation treatment for individuals who have not responded adequately to antidepressant medications. The investment underscores confidence in Neurolief's innovative approach to treating challenging mental health conditions.

Neurolief Secures $6M Post-FDA Approval Funding

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing